- Canada
- /
- Healthtech
- /
- TSXV:KOVO
Kovo HealthTech Full Year 2022 Earnings: US$0.006 loss per share (vs US$0.083 loss in FY 2021)
Kovo HealthTech (CVE:KOVO) Full Year 2022 Results
Key Financial Results
- Revenue: US$10.5m (up 79% from FY 2021).
- Net loss: US$250.0k (loss narrowed by 91% from FY 2021).
- US$0.006 loss per share (improved from US$0.083 loss in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Kovo HealthTech shares are up 2.9% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Kovo HealthTech has 4 warning signs we think you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if Kovo+ Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSXV:KOVO
Medium-low and slightly overvalued.